$31.91 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter

Share on StockTwits

Equities analysts expect that Heron Therapeutics Inc (NASDAQ:HRTX) will post sales of $31.91 million for the current quarter, according to Zacks. Four analysts have issued estimates for Heron Therapeutics’ earnings, with the highest sales estimate coming in at $34.60 million and the lowest estimate coming in at $26.80 million. Heron Therapeutics posted sales of $17.28 million in the same quarter last year, which suggests a positive year-over-year growth rate of 84.7%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, August 14th.

On average, analysts expect that Heron Therapeutics will report full year sales of $119.99 million for the current year, with estimates ranging from $114.40 million to $124.85 million. For the next year, analysts anticipate that the business will post sales of $211.55 million, with estimates ranging from $185.00 million to $245.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). The business had revenue of $31.60 million for the quarter, compared to analysts’ expectations of $28.04 million. Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The business’s quarterly revenue was up 172.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.09) earnings per share.

Several equities analysts have recently commented on HRTX shares. Northland Securities reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, March 11th. Cantor Fitzgerald set a $50.00 target price on Heron Therapeutics and gave the company a “buy” rating in a research note on Friday, February 22nd. Stifel Nicolaus reiterated a “buy” rating and set a $54.00 target price on shares of Heron Therapeutics in a research note on Friday, February 22nd. ValuEngine upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Cowen reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, May 9th. Three analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $51.20.

Heron Therapeutics stock opened at $18.06 on Friday. The company has a market cap of $1.45 billion, a PE ratio of -7.40 and a beta of 1.45. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06. Heron Therapeutics has a 52 week low of $16.20 and a 52 week high of $42.90.

In other news, Director Waage Christian acquired 1,400 shares of Heron Therapeutics stock in a transaction that occurred on Wednesday, May 15th. The shares were purchased at an average cost of $18.04 per share, for a total transaction of $25,256.00. Following the completion of the purchase, the director now directly owns 1,400 shares of the company’s stock, valued at approximately $25,256. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 12.56% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new position in Heron Therapeutics during the fourth quarter worth $13,679,000. Boston Advisors LLC lifted its stake in Heron Therapeutics by 443.9% in the first quarter. Boston Advisors LLC now owns 134,559 shares of the biotechnology company’s stock valued at $3,288,000 after buying an additional 109,819 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its stake in Heron Therapeutics by 144.6% in the fourth quarter. Los Angeles Capital Management & Equity Research Inc. now owns 19,690 shares of the biotechnology company’s stock valued at $511,000 after buying an additional 11,640 shares during the last quarter. Legal & General Group Plc lifted its stake in Heron Therapeutics by 6.5% in the fourth quarter. Legal & General Group Plc now owns 27,564 shares of the biotechnology company’s stock valued at $716,000 after buying an additional 1,679 shares during the last quarter. Finally, Congress Park Capital LLC lifted its stake in Heron Therapeutics by 32.2% in the fourth quarter. Congress Park Capital LLC now owns 46,575 shares of the biotechnology company’s stock valued at $1,208,000 after buying an additional 11,350 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Read More: What are the benefits of a balanced fund?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$31.91 Million in Sales Expected for Heron Therapeutics Inc  This Quarter
$31.91 Million in Sales Expected for Heron Therapeutics Inc This Quarter
Shaftesbury  Rating Reiterated by Peel Hunt
Shaftesbury Rating Reiterated by Peel Hunt
Hardide’s  “Corporate” Rating Reiterated at FinnCap
Hardide’s “Corporate” Rating Reiterated at FinnCap
Deutsche Bank Reaffirms “Hold” Rating for SSE
Deutsche Bank Reaffirms “Hold” Rating for SSE
Zacks: Brokerages Anticipate Proto Labs Inc  Will Post Quarterly Sales of $116.40 Million
Zacks: Brokerages Anticipate Proto Labs Inc Will Post Quarterly Sales of $116.40 Million
Research Analysts Offer Predictions for Cimarex Energy Co’s Q2 2019 Earnings
Research Analysts Offer Predictions for Cimarex Energy Co’s Q2 2019 Earnings


© 2006-2019 Ticker Report